Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
about
Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach.IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival.Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.ALKBH7 drives a tissue and sex-specific necrotic cell death response following alkylation-induced damage.Management and treatment recommendations for World Health Organization Grade III and IV gliomas.Two cases of cutaneous drug eruption associated with temozolomide therapy for glioblastoma.Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma.Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study.Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue.
P2860
Q33424898-FFEFF01B-E0C8-4699-8900-36C382361F12Q36494977-65830145-DBEB-4465-B4E0-78C063A538ADQ36562205-D72449E7-2D7A-4485-86F1-3999110F68D2Q38393472-AB0E471C-3842-4E40-ADB3-B551436C0017Q38480274-A1F15B79-97F6-48C4-B759-0B2335D69269Q38730989-ABCB8416-7045-40A1-ABDF-682BC88E65B7Q38858481-C317129A-A19D-4513-84F2-5A7346F11245Q41335643-074F565F-7F9F-41E2-B606-2E366CD382A3Q41706326-4F6D3C37-E872-4E22-959E-00899454835EQ43056413-8C6D6D3D-BDDB-4B7B-8687-9DF0B715961CQ47110239-231D4B34-F76A-4660-9C35-A2F8666C86E9Q48469935-82880FB1-F11B-42A5-9A4B-62F4815DE983Q50130110-AA2EF099-C722-4409-B07B-6ACE5806B932Q52715248-4D900615-8F95-41CC-97CF-3F1FAA0C89DB
P2860
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
@en
type
label
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
@en
prefLabel
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
@en
P2093
P1433
P1476
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
@en
P2093
Louise Baker
Mohan Hingorani
Sanjay Dixit
Vicki Walmsley
P304
P356
10.1097/CAD.0B013E328356F5B0
P577
2012-11-01T00:00:00Z